Trial Profile

A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

03 Oct 2023 Status changed from recruiting to active, no longer recruiting.
19 Jul 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2024.
19 Jul 2022 Planned primary completion date changed from 31 May 2022 to 1 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com